Business
VYNE Therapeutics Announces the Appointment of Patrick G. LePore to its Board of Directors
BRIDGEWATER, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the Board of
About this update from Vyne Therapeutics Inc.
[{"type":"text","content":"BRIDGEWATER, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the Board of Directors of the Company appointed Mr. Patrick G. LePore to serve as a director of the Company, effective as of September 10, 2020.\n “We are delighted to welcome Pat to our Board. Pat brings extensive experience from a long and successful career as a senior level executive and board member for several highly regarded companies in the pharmaceutical sector,” said David Domzalski, President and Chief Executive Officer of VYNE. “As VYNE establishes itself as a commercial stage pharmaceutical company, it is important to have Board members with the appropriate areas of expertise. Pat has relevant experience in M&A, operations and the sales and marketing of branded pharmaceuticals, which will be very helpful as we make preparations for our second commercial launch in 2020 and build our franchise in dermatology. We are confident that he will bring valuable insight and make important contributions to our company.” Mr. LePore stated “I am enthusiastic to be joining the Board of Directors of VYNE, and to work with a highly dedicated organization. VYNE is committed to making a meaningful difference in the lives of patients, and has a strong culture of innovation, a recent track record of regulatory approvals and a great opportunity to build valuable therapeutic brands.” Mr. LePore has more than 40 years of experience in the pharmaceutical industry, in both private and public sectors, and with board and operational experience in each. He served as Chairman, Chief Executive Officer and President of Par Pharmaceutical Companies, Inc. from September 2006 to 2012. During his tenure at Par, Mr. LePore oversaw the management of over 2,000 employees with facilities across the United States and India. He also directed the growth of its brand business, Strativa, its sales force and the acquisition of several specialty pharmaceutical products. Through Mr. LePore’s leadership, Par increased its value and market presence culminating in its sale to affiliates of TPG Capital for approximately $2 billion in 2012. He remained as chairman of the new company through its sale to Endo International for approximately $8 billion in 2015. Mr. LePore began his career with Hoffmann-LaRoche in 1978 as a sales repres...